Last week, U.S. equities extended their rally before momentum faded. The S&P 500 and Nasdaq hit record highs early in the week, fueled by excitement around artificial intelligence and hopes for Federal Reserve rate cuts. Mega-cap tech stocks led the charge, with investors piling into growth and innovation themes. However, sentiment cooled toward the end of the week as Treasury yields rose and stronger-than-expected economic data raised doubts about how soon the Fed might ease policy. Energy and financials lagged, while tech and communication services stayed resilient.
Overall, markets reflected a push-and-pull between optimism over innovation and earnings strength and caution about tighter financial conditions. The week ended with stocks modestly lower but with a more cautious tone setting in, suggesting investors are reassessing the balance between growth potential and macro headwinds. The market still only gave back .30% from a record close..
Name: Willem A. Meintjes
Position: Chief Financial Officer
Transaction Date: 09-25-2025 Shares Bought: 3,400 shares an Average Price Paid of $78.03 for Cost: $265,302
Name: Sandeep Bharathi
Position: President of the Data Center Group
Transaction Date: 09-25-2025 Shares Bought: 3,400 shares an Average Price Paid of $78.03 for Cost: $265,302
Name: Chris Koopmans
Position: President and COO
Transaction Date: 09-25-2025 Shares Bought: 6,800 shares an Average Price Paid of $78.03 for Cost: $530,604
Name: Matthew J. Murphy
Position: Chairman of the Board and CEO
Transaction Date: 09-25-2025 Shares Bought: 13,600 shares an Average Price Paid of $77.09 for Cost: $1,048,424
Company: Marvell Technology Inc. (MRVL):
Marvell Technology, Inc., together with its consolidated subsidiaries, is a leading provider of infrastructure semiconductor solutions spanning from the data center core to the network edge. As a fabless semiconductor company, Marvell delivers high-performance standard and semi-custom devices with expertise in designing and scaling complex System-on-a-Chip architectures that integrate analog, mixed-signal, and digital signal processing functions. Its solutions support the data-driven economy by combining advanced intellectual property, system-level knowledge, and proprietary security firmware. Marvell’s technologies serve a wide range of industries, including data centers, carrier infrastructure, enterprise networking, consumer, automotive, and industrial markets.
Willem A. Meintjes has served as Chief Financial Officer of Marvell Technology, Inc. since January 2023. He joined the company in June 2016 as Senior Vice President of Finance and was later promoted to Chief Accounting Officer and Treasurer. In his current role, he oversees Marvell’s financial planning and strategy, accounting and reporting, treasury and tax functions, as well as investor relations. Prior to Marvell, Mr. Meintjes held senior finance positions at Newport Corporation and International Rectifier, where he served as Vice President and Corporate Controller. He earned a Bachelor of Commerce in Accounting from the University of Johannesburg.
Sandeep Bharathi has served as President of the Data Center Group at Marvell Technology, Inc. since 2025. He joined the company in 2019 as Senior Vice President of Central Engineering, where he was responsible for advanced technology and process development. Prior to Marvell, he was Vice President of Engineering at Intel, overseeing FPGA product and technology development. Over the course of his career, Mr. Bharathi has led the introduction of numerous CPUs, GPUs, FPGAs, SoCs, and custom silicon designs, driving significant revenue growth. He holds a B.E. in Electronics Engineering from Bangalore University, an M.S. in Electrical Engineering from the New Jersey Institute of Technology, and is an alumnus of the Stanford Executive Programme.
Chris Koopmans has served as President and Chief Operating Officer of Marvell Technology since July 2025. In this role, he oversees the Multimarket Business Group along with the company’s global business operations, including sales, marketing, information technology, and corporate development. He joined Marvell in 2016 as Executive Vice President of Marketing and Sales, following his tenure at Citrix Systems, Inc., where he was Vice President and General Manager for Service Provider Platforms. Mr. Koopmans earned a B.S. in Computer Engineering with Highest Honors from the University of Illinois and pursued graduate studies in Electrical and Computer Engineering as a National Science Foundation Graduate Research Fellow.
Matthew J. Murphy has served as Chief Executive Officer of Marvell Technology, Inc. since July 2016 and assumed the role of Chairman of the Board in June 2023. He leads the company’s strategic transformation and growth as a leading semiconductor provider of data infrastructure solutions. Prior to Marvell, Mr. Murphy spent more than two decades at Maxim Integrated, where he held senior leadership roles including Executive Vice President of Business Units and Sales and Marketing. He holds a Bachelor of Arts degree from Franklin & Marshall College and completed the Stanford Corporate Program, combining a strong foundation in liberal arts with executive-level corporate leadership training.
Insomniac Hedge Fund Guy Opinion:
Marvell Technology (MRVL) is a second-derivative AI play. If Nvidia is the shovel-seller in the gold rush, Marvell is selling the rails and wheelbarrows. That’s a sweet spot, but not immune to corrections. It’s a growth stock dressed in networking clothes—fun to own in bull phases, brutal in drawdowns.
-
Long-term: Solid bet on data-centric growth (AI, 5G, cloud).
-
Short-term: Expect volatility. Great trading stock if you time support/resistance right .
-
Positioning: Not one you go all-in on. A 5–8% portfolio allocation fits the “don’t risk too much on one idea” rule.
⚠️ Not financial advice—just my battle-hardened view. If you want exposure to the AI ecosystem without paying Nvidia’s premium, MRVL is one of the smarter horses to ride. But keep a hand near the eject button when sentiment turns.
Name: Michael J. Endres
Position: Director
Transaction Date: 09-25-2025 Shares Bought: 10,000 shares an Average Price Paid of $52.95 for Cost: $529,500
Company: Worthington Enterprises Inc. (WOR):
Worthington Enterprises, Inc., headquartered in Columbus, Ohio, is an industrial manufacturing company operating through two segments: Consumer Products and Building Products. The Consumer Products segment offers torches, lighters, precision and specialty tools, drywall accessories, propane and helium cylinders, balloon kits, gas grills, and pizza ovens. These products are distributed primarily through mass merchandisers, retailers, and distributors under brands such as Balloon Time, Bernzomatic, Coleman, Garden-Weasel, and Worthington Pro Grade. The Building Products segment provides pressurized containment solutions, including refrigerant and liquefied petroleum gas cylinders, well water and expansion tanks, specialty tanks for fire suppression and chemicals, as well as ceiling suspension systems for residential, commercial, and industrial applications. Founded in 1955, the company was formerly known as Worthington Industries, Inc.
Michael J. Endres has served as a director of Worthington Enterprises, Inc. since 1999 and currently holds the position of Lead Independent Director. He chairs the Nominating and Governance Committee and serves on the Executive and Compensation Committees. Mr. Endres co-founded Stonehenge Partners, Inc., a private equity investment firm, in 1999 and currently acts as Senior Advisor, providing strategic guidance on financial a nalysis, acquisitions, and industry trends. His extensive experience includes roles as Vice Chairman of Banc One Capital Holdings Corporation and Chairman of Banc One Capital Partners. Mr. Endres began his investment banking career in 1971 with The Ohio Company and holds a Bachelor of Science from Miami University in Oxford, Ohio.
Insomniac Hedge Fund Guy-style, no-sleep-till-profit take on Worthington Enterprises (WOR):Worthington Enterprises (WOR): The Sleepy Steel Offspring That’s Trying to Party
Born from the December 2023 Worthington Steel spin-off, Worthington Enterprises reinvented itself as a “consumer and building products” player — think propane tanks, Balloon Time helium kits, Bernzomatic torches, HVAC parts, and ceiling grids. Not sexy, but it’s the stuff you don’t notice until you need it at 2 a.m.
Q1 FY2026 numbers weren’t bad: EPS $0.74, revenue ~$304M. That’s a beat, but the stock still drifts like an unloved stepchild of the industrial sector. Consumer volumes are soft, building products are doing the heavy lifting.
This isn’t a high-growth tech rocket — it’s a cash-flow grinder with brands that sneak into your backyard BBQs and construction sites. The question is whether management can spin this into more than a utility-like slog. Right now, it’s a “prove it” story.
Want me to put WOR through the Earnings Volatility lens (green/yellow/red) for your trading list?
Name: Jason C. Rebrook
Position: Director
Transaction Date: 09-18-2025 Shares Bought: 10,000 shares an Average Price Paid of $24.17 for Cost: $241,670
Transaction Date: 09-19-2025 Shares Bought: 10,000 shares an Average Price Paid of $24.16 for Cost: $241,580
Company: Archrock Inc. (AROC):
Archrock, Inc. is a U.S.-based energy infrastructure company operating through two segments: Aftermarket Services and Contract Operations. The company delivers natural gas compression services by designing, sourcing, owning, installing, operating, maintaining, and repairing a fleet of compression equipment. In addition to packaging reciprocating and rotary screw natural gas compressors for sale or contract use, it provides customers with maintenance, overhauls, parts, and equipment reconfiguration services. Founded in 1990 and headquartered in Houston, Texas, Archrock serves both independent and integrated oil and natural gas producers, gatherers, and transporters.
Jason C. Rebrook has served as a director of Archrock, Inc. since 2020. He is the Chief Executive Officer of Harvest Midstream and the Chief Executive Officer of JDH Capital. His previous experience includes senior leadership roles at GE Capital and Chevron, where he was responsible for energy operations and acquisitions. Mr. Rebrook earned a Bachelor of Science in Petroleum Engineering from Marietta College and an MBA from Duke University’s Fuqua School of Business.
Insomniac Hedge Fund Guy Opinion::
Archrock (AROC) is the 800-lb gorilla of natural gas compression — and it’s flexing. Revenues and EBITDA are ripping higher, management just hiked guidance, and the Permian Basin build-out plus bolt-on acquisitions like TOPS are fueling serious scale. This is a picks-and-shovels play on U.S. natural gas growth, and Archrock gets paid whether producers are minting money or just keeping wells alive.
But don’t ignore the dark side: this beast carries heavy leverage, and in a downturn those senior notes will bite. Free cash flow swings around like a rodeo bull, and margins are hostage to utilization rates. Still, if you want midstream torque without betting directly on gas prices, AROC is a high-octane way to ride the shale boom — just buckle up for some balance-sheet turbulence.
Name: Menelas N. Pangalos
Position: Director
Transaction Date: 09-22-2025 Shares Bought: 95,785 shares an Average Price Paid of $2.66 for Cost: $254,788
Company: Absci Corp. (ABSI):
Absci Corp. is a biotechnology company focused on developing generative AI–driven drugs, with a specialization in creating novel antibody therapies. Its Integrated Therapeutic Creation platform combines generative AI models with synthetic biology to simultaneously optimize multiple therapeutic properties, including those targeting difficult-to-treat conditions. This approach is designed to advance beyond traditional biologic discovery, reduce development timelines, and increase the probability of clinical success. By bridging the gap from drug discovery to drug production, Absci seeks to deliver first-in-class and best-in-class antibody treatments for patients with unmet medical needs.
Menelas N. Pangalos joined the board of directors of Absci Corporation in January 2024. He previously had a distinguished career in biopharmaceutical research and development, most notably at AstraZeneca, where he led the BioPharmaceuticals R&D division after holding multiple senior R&D leadership roles. He earned an undergraduate degree in biochemistry from the University of London, followed by a Ph.D. in neurochemistry. In addition, he holds an honorary doctorate and is a Fellow of several prominent academic institutions.
Insomniac Hedge Fund Guy Opinion:
Absci (ABSI) is swinging for the fences—AI meets wet lab in a biotech moonshot. They’re betting machine learning can crank out new drugs faster than Big Pharma’s armies of lab coats. The story’s sexy: generative AI designing proteins, “zero-shot” drug discovery, the whole science-fiction package. The reality? Still burning cash, still waiting for proof beyond hype decks and partnerships that don’t scream revenue yet. Stock trades like a biotech lottery ticket—spikes on news, bleeds on silence. If the dream works, ABSI rewrites pharma’s playbook. If not, it’s another “AI revolution” that dies in a petri dish. High-risk, high-reward, and not for the faint-hearted.
Name: Stephen Aiello
Position: Director
Transaction Date: 09-22-2025 Shares Bought: 133,334 shares an Average Price Paid of $1.66 for Cost: $221,334
Company: GrowGeneration Corp. (GRWG):
GrowGen is like the rebel supplier of the green world — the U.S.’s largest specialty hydroponics and organic gardening chain. (GrowGeneration Corporation) They hawk everything from high-end lighting rigs to soil, nutrients, climate control gear, and even benching and storage systems. (MarketWatch)
But don’t let the hype fool you — it’s a bleeding business. Revenues are slipping, and losses are deep: they’re still in the red, burning cash trying to scale. (Barchart.com) Their “MMI” storage division is good noise — it’s profitable enough that they’re exploring strategic options (read: maybe spin it off or sell) so they can refocus on their core grow-gear hustle. (The Wall Street Journal)
So yeah: GrowGen is badass in ambition and footprint, but it’s also a storm of financial risk. If they pull off a turnaround or smart divestment, the upside could sting.
Name: Damien Lamendola
Position: Chief Executive Officer, 10% Owner
Transaction Date: 09-10-2025 Shares Bought: 896,903 shares an Average Price Paid of $1.06 for Cost: $950,000
Company: Marpai Inc. (MRAI):
Marpai, Inc. is a nationwide technology-driven healthcare Third-Party Administrator that leverages artificial intelligence, data analytics, and cost-management strategies to help clients lower healthcare costs while enhancing health outcomes for employees and their families. The company supports self-insured employers by processing members’ healthcare claims and delivering cost-efficient, intelligent healthcare solutions. Marpai also partners with healthcare providers—including physicians, hospitals, clinics, and other service and product providers—to improve the quality and delivery of care.
Damien Lamendola is the Chief Executive Officer and a Director of Marpai, Inc. He was appointed to the board on April 1, 2021, and assumed the role of CEO in November 2023. Mr. Lamendola has an extensive career in the healthcare industry, having founded WellDyne, a pharmacy benefit manager, in 2002, and Continental Benefits, a third-party administrator, in 2013. He also serves as CEO of HillCour Holding Corporation, an investment firm with ownership interests in multiple healthcare companies. He holds a Bachelor of Science degree from McNeese State University and an MBA from Washington University, providing a strong foundation in corporate management and strategic leadership.
Insomniac Hedge Fund Guy Opinion:
Financially, Marpai is early-stage and loss-making. Q2 2025 results show liabilities exceeding assets, and trailing EBITDA remains negative (~$9.1M in 2024). Revenue growth is modest, primarily from partner arrangements, with no recurring subscription-style revenue reported. The company’s financial position is fragile, evidenced by its transfer from Nasdaq to OTCQX following minimum equity compliance issues.
Insider activity provides a counterpoint: CEO Damien Lamendola purchased ~897k shares recently (~$942k), signaling confidence in the business outlook and potential near-term catalysts. Short interest is moderate, and stock volatility has been high, including a ~40% drop post-listing transfer.
From a risk-reward perspective, Marpai represents a classic high-beta, binary biotech/health-tech story: upside hinges on adoption of its AI platform, expansion of partner contracts, and potential margin improvement, while downside risk is significant due to operating losses, weak balance sheet, and competitive pressures. Investors seeking exposure to early-stage AI-health solutions could view MRAI as a speculative, high-risk, high-reward play, but capital preservation is a serious concern until positive revenue or profit inflection points are reached.
Listen to our The Insiders Fund Not So Daily Podcast and Follow us on Twitter for real-time commentary and insider buying alerts at https://twitter.com/theinsidersfund
If you are a QUALIFIED INVESTOR and are interested in learning how you can be part of the Insiders Fund, schedule some time with me here.
This blog is solely for educational purposes and the author’s own amusement. IT IS NOT INVESTMENT ADVICE. Think of the blog as part of my personal investment journal that I am willing to share with the DIY investor. There are also many parts that I am not willing to share if I think it could influence trading action or be detrimental to the Fund’s partners. We could be long, short, or have no position at all in any of the stocks mentioned and express no written or implied obligation to disclose any of that. Nothing contained here constitutes a recommendation to buy or sell any security. Investing involves risk, including the possible loss of principal, and past performance is not indicative of future results.
“The insomniac hedge fund guy” is a moniker Harvey Sax, the portfolio manager for The Insiders Fund” has used from time to time on email, blog ,and social media posts. While Mr. Sax is the portfolio manager of The Insiders Fund, these posts are not communications from, nor endorsed by, Alpha Wealth Funds, LLC or any of its managed funds. References to Alpha Wealth Funds or its affiliates are for identification only and do not imply sponsorship or approval.”
The Insiders Fund and its blogs and posts are not affiliated with, endorsed by, or sponsored by any of the companies mentioned herein. All company names, logos, and trademarks belong to their respective owners. The use of company logos is solely for descriptive and illustrative purposes under fair use. Any information provided is based on publicly available data and should not be considered financial, investment, or legal advice. Readers should conduct their own research or consult with a professional before making any investment decisions.
Insiders sell the stock for many reasons, but they generally buy for just one – to make money. You’ve always heard the best information is inside information. Everyone with any stock market experience pays close attention to what insiders are doing. After all, who knows a business better than the people running it? Officers, directors, and 10% owners are required to inform the public through a Form 4 Filing of any transaction, buy, sell, exercise, or any other within 48 hours of doing so. This info is available for free from the SEC’s Web site, Edgar, although we subscribe to SECForm4 as they provide a way to manage and make sense of the vast realms of data. I’ve tried a lot of vendors. SECForm4 is one of the smaller ones, but I like supporting Frank. He is not arrogant. He’s helpful and has great prices. He also trades on his own data, so I like people that eat what they kill.
The bar is different from selling because the natural state of management is to be a seller. This is because most companies provide significant amounts of management compensation packages as stock and options. Therefore, we analyze unusual patterns with selling, such as insiders selling 25 percent or more of their holdings or multiple insiders selling near 52-week lows. Another red flag is large planned sale programs that start without warning. Unfortunately, the public information disclosure requirements about these programs, referred to as Rule 10b5-1, are horrendously poor. Also, planned sales that pop up out of nowhere are basically sales and are seeking cover under this corporate welfare loophole. I also generally ignore 10 percent shareholders as they tend to be OPM (other people’s money) and perhaps not the smart money on which we are trying to read the tea leaves. I say generally because some 10% shareholders are great investors. Think Warren Buffett and others
Of course, insiders can also be wrong about their Company’s prospects. Don’t let anyone fool you into believing they never make mistakes. Do your own analysis. They can easily be wrong, and in many cases, maybe most cases, have no more idea what the future may hold than you or me. In short, you can lose money following them. We have, and we curse aloud; what were they thinking!
We like Fly on the Wall for keeping up with what events might be happening, analysts’ comments, and whatever else could be moving the stock. Dow Jones news service is an essential tool, but many services pick up their feed like they do Bloomberg. For quick financial analysis, it’s hard to beat Old School Value.
A big callout to my assistant Ambreen who sets up this conversation by listing the notable buys that I’ve identified as soon as practically possible. She probes the 10k for a reasonable description of the business. I’ve found that to be the most accurate and succinct place to find out what a business actually does. When I have time, over the weekend, I’ll add some preliminary analysis to the Opinion at the end. Sometimes I won’t update this for a couple of weeks or more. A good way to use this blog is as I do, it’s a reference point and filing cabinet for various stocks with notable insider buying. It’s one of many tools I use. I regularly live on Chat GPT, Gemini, Claude, and occasionally Microsoft Copilot. I find the footnotes research very helpful in eliminating errors from AI hallucinations but these opinions are likely to contain inaccuracies due to the nature of the LLM’s.
The Insiders Fund is for qualified investors and by Prospectus only. Nothing herein should be construed otherwise. THE INSIDERS FUND prefers to invest in companies at or near prices that management has been willing to invest significant amounts of their own money in, but we have no requirement to do so. We also invest in many companies in anticipation of future insider buying or with the expectation that there is none at all.
You can be an insider, too– by clicking here
Prosperous Trading,
